280 related articles for article (PubMed ID: 36070054)
21. Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A.
Zhao Y; Hu J; Sun X; Yang K; Yang L; Kong L; Zhang B; Li F; Li C; Shi B; Hu K; Sun A; Ge J
Clin Transl Med; 2021 May; 11(5):e402. PubMed ID: 34047466
[TBL] [Abstract][Full Text] [Related]
22. Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5.
Zhu K; Gou F; Zhao Z; Xu K; Song J; Jiang H; Zhang F; Yang Y; Li J
Leuk Res; 2024 Jun; 141():107451. PubMed ID: 38663164
[TBL] [Abstract][Full Text] [Related]
23. ALKBH5 inhibits the SIRT3/ACC1 axis to regulate fatty acid metabolism via an m6A-IGF2BP1-dependent manner in cervical squamous cell carcinoma.
Zhen L; Pan W
Clin Exp Pharmacol Physiol; 2023 May; 50(5):380-392. PubMed ID: 36705046
[TBL] [Abstract][Full Text] [Related]
24. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
[TBL] [Abstract][Full Text] [Related]
25. ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis.
Yu H; Yang X; Tang J; Si S; Zhou Z; Lu J; Han J; Yuan B; Wu Q; Lu Q; Yang H
Mol Ther Nucleic Acids; 2021 Mar; 23():27-41. PubMed ID: 33376625
[TBL] [Abstract][Full Text] [Related]
26. ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages.
Hua X; Xu Q; Wu R; Sun W; Gu Y; Zhu S; Liu X; Lv T; Song Y
J Exp Clin Cancer Res; 2024 Jun; 43(1):164. PubMed ID: 38872221
[TBL] [Abstract][Full Text] [Related]
27. ALKBH5-mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9.
Li Y; Yan B; Wang X; Li Q; Kan X; Wang J; Sun Y; Wang P; Tian L; Liu M
J Cell Mol Med; 2022 Jan; 26(2):385-398. PubMed ID: 34850551
[TBL] [Abstract][Full Text] [Related]
28. [Berberine inhibits erastin-induced ferroptosis of mouse hippocampal neuronal cells possibly by activating the Nrf2-HO-1/GPX4 pathway].
Huang Q; Ji D; Tian X; Ma L; Sun X
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):937-943. PubMed ID: 35790446
[TBL] [Abstract][Full Text] [Related]
29. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.
Lv D; Zhong C; Dixit D; Yang K; Wu Q; Godugu B; Prager BC; Zhao G; Wang X; Xie Q; Bao S; He C; Heiland DH; Rosenfeld MG; Rich JN
Mol Cell; 2023 Dec; 83(23):4334-4351.e7. PubMed ID: 37979586
[TBL] [Abstract][Full Text] [Related]
30. m
Tang B; Yang Y; Kang M; Wang Y; Wang Y; Bi Y; He S; Shimamoto F
Mol Cancer; 2020 Jan; 19(1):3. PubMed ID: 31906946
[TBL] [Abstract][Full Text] [Related]
31. ALKBH5-YTHDF2 m6A modification axis inhibits rheumatoid arthritis progression by suppressing NLRP3.
Xiao J; Cai X; Wang R; Zhou W; Ye Z
Biochem Biophys Res Commun; 2023 Aug; 668():70-76. PubMed ID: 37244037
[TBL] [Abstract][Full Text] [Related]
32. METTL16 epigenetically enhances GPX4 expression via m6A modification to promote breast cancer progression by inhibiting ferroptosis.
Ye F; Wu J; Zhang F
Biochem Biophys Res Commun; 2023 Jan; 638():1-6. PubMed ID: 36434904
[TBL] [Abstract][Full Text] [Related]
33. The RNA demethylase ALKBH5 promotes the progression and angiogenesis of lung cancer by regulating the stability of the LncRNA PVT1.
Shen W; Pu J; Zuo Z; Gu S; Sun J; Tan B; Wang L; Cheng J; Zuo Y
Cancer Cell Int; 2022 Nov; 22(1):353. PubMed ID: 36376862
[TBL] [Abstract][Full Text] [Related]
34. The m6A demethylase ALKBH5 controls trophoblast invasion at the maternal-fetal interface by regulating the stability of
Li XC; Jin F; Wang BY; Yin XJ; Hong W; Tian FJ
Theranostics; 2019; 9(13):3853-3865. PubMed ID: 31281518
[TBL] [Abstract][Full Text] [Related]
35. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.
Yu F; Wei J; Cui X; Yu C; Ni W; Bungert J; Wu L; He C; Qian Z
Nucleic Acids Res; 2021 Jun; 49(10):5779-5797. PubMed ID: 34048572
[TBL] [Abstract][Full Text] [Related]
36. ALKBH5 targets ACSL4 mRNA stability to modulate ferroptosis in hyperbilirubinemia-induced brain damage.
Zhou J; Tang J; Zhang C; Li G; Lin X; Liao S; Luo J; Yu G; Zheng F; Guo Z; Shao W; Hu H; Xu L; Wu S; Li H
Free Radic Biol Med; 2024 Aug; 220():271-287. PubMed ID: 38734267
[TBL] [Abstract][Full Text] [Related]
37. HPV E7-drived ALKBH5 promotes cervical cancer progression by modulating m6A modification of PAK5.
Huo FC; Zhu ZM; Du WQ; Pan YJ; Jiang X; Kang MJ; Liu BW; Mou J; Pei DS
Pharmacol Res; 2023 Sep; 195():106863. PubMed ID: 37480971
[TBL] [Abstract][Full Text] [Related]
38. Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer.
Zhang D; Ning J; Okon I; Zheng X; Satyanarayana G; Song P; Xu S; Zou MH
Cell Death Dis; 2021 May; 12(6):518. PubMed ID: 34016959
[TBL] [Abstract][Full Text] [Related]
39. ALKBH5 Promotes the Proliferation of Glioma Cells via Enhancing the mRNA Stability of G6PD.
Liu Z; Chen Y; Wang L; Ji S
Neurochem Res; 2021 Nov; 46(11):3003-3011. PubMed ID: 34297301
[TBL] [Abstract][Full Text] [Related]
40. m
Jin D; Guo J; Wu Y; Yang L; Wang X; Du J; Dai J; Chen W; Gong K; Miao S; Li X; Sun H
Mol Cancer; 2020 Feb; 19(1):40. PubMed ID: 32106857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
